Parkinson's disease (PD) is a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons and/or loss od neuronal projections, in several dopaminergic networks. Current treatments for idiopathic PD rely mainly on the use of pharmacologic agents to improve motor symptomatology of PD patients. Nevertheless, so far PD remains an incurable disease. Therefore, it is of utmost importance to establish new therapeutic strategies for PD treatment. Over the last 20 years, several molecular, gene and cell/stem-cell therapeutic approaches have been developed with the aim of counteracting or retarding PD progression. The scope of this review is to provide an overview of PD related therapies and major breakthroughs achieved within this field. In order to do so, this review will start by focusing on PD characterization and current treatment options covering thereafter molecular, gene and cell/stem cell-based therapies that are currently being studied in animal models of PD or have recently been tested in clinical trials. Among stem cell-based therapies, those using MSCs as possible disease modifying agents for PD therapy and, specifically, the MSCs secretome contribution to meet the clinical challenge of counteracting or retarding PD progression, will be more deeply explored.
Introduction
Parkinson's disease (PD) is the most common motor-related disorder in middle or late life, affecting millions worldwide (Pereira and Aziz, 2006) . It was first described in 1817 by James Parkinson on his original "An essay on the shaking palsy" as "paralysis agitans", after observing signs of tremor, festinating gait and flexed posture in six patients (Parkinson, 1817; Pereira and Aziz, 2006) . "Paralysis agitans" was later named "maladie de Parkinson" or Parkinson's disease in 1888 by Charcot (Charcot, 2002) . The scope of this review is to provide an overview on PD and related therapies, including the most recent trends within this field. For that, it will first characterize PD and will focus thereafter on clinical features and diagnosis, as well as on current clinical approaches and emerging molecular and stem cell-based therapies, particularly those using mesenchymal stem cells (MSCs). An overview of new candidate drugs and the current status of gene therapy for PD treatment will also be provided. All the therapeutic approaches outlined in this review aiming at treating the motor symptoms of PD are summarized in Fig. 1 .
Parkinson's disease
Parkinson's disease is a slowly progressive neurodegenerative disease, primarily characterized by the increasing loss of dopaminergic (DAergic) neurons. This happens in several dopaminergic networks (mesocortical, mesolimbic and nigro-striatal pathways), presenting a stronger impact in the ventral tier of the substantia nigra pars compacta (SNpc) within the mesostriatal/nigrostriatal pathway (Cummins and Barker, 2012; Koller, 2003; Pereira and Aziz, 2006; Teixeira et al., 2013) . Loss of substantia nigra (SN) neurons leads to less DAergic innervations and consequently to striatal dopamine (DA) deficiency, the main responsible for most of the sensory-motor symptoms of PD (Dauer and Przedborski, 2003) . By the time PD motor symptoms appear, approximately 60% of DAergic neurons in SN and 80% of striatal DA terminals have already been lost (Beach et al., 2008; Cheng et al., 2010; Dauer and Przedborski, 2003; Nandhagopal et al., 2008) . Although the etiology of SN degeneration is unknown, in addition to the motor symptomatology, the presence of Lewy bodies (LBs) is another hallmark feature of PD and is typically used as a post-mortem confirmation of the disease (Olanow and Brundin, 2013) . LBs are distinctive intracytoplasmatic inclusions, containing a variety of cellular proteins, being a-synuclein the most abundant one (Benskey et al., 2016 ). The precise reason why LBs form and its role in pathogenesis of PD remains undetermined (Dickson et al., 2009) . However, in recent years, it has become clear that the initial sites displaying LBs are the dorsal motor nucleus of the vagus in the brainstem and the olfactory bulb, which is described as stage I of the disease. This staging was firstly proposed by Braak and colleagues (Braak et al., 2003a) , demonstrating that the disease most likely progresses in an upward direction via the pons (stage II) to the midbrain (stage III), followed by the basal prosencephalon and mesocortex (stage IV), and eventually reaching the temporal cortex and neocortex (stages V and VI) (Braak et al., 2003b) . However, it is only at stage III, when DAergic neuronal death and striatal nerve terminals exceed a critical threshold (as mentioned above) that motor features of PD become evident. This means that there is a substantial pre-symptomatic period when the disease is hidden possibly due to the existence of compensatory mechanisms (Navntoft and Dreyer, 2016) .
There has been converging evidence suggesting that PD can start in the gut, before spreading to the olfactory bulb and caudal brainstem and then progressing through the brainstem and the diencephalon until it eventually reaches the cortex (Jankovic, 2016) . Based on this idea, Gjerløff and colleagues (Gjerloff et al., 2015) proposed that in addition to the loss in dopaminergic innervation, catecholaminergic and cholinergic neurons are also vulnerable and affected on PD (Gjerloff et al., 2015) . Through an imaging acetylcholinesterase (AChE) density of the peripheral organs using positron emission tomography (PET), these authors found not only loss of cholinergic innervation in the gastrointestinal tract, but also that the pancreas seems to be affected, since it receives innervation from the dorsal vagal motor nucleus (DMV). However, no studies have yet analyzed histologically the distribution of cholinergic markers in PD patient's pancreas, thereby raising the question about which structures within it exhibit the decreased AChE expression and if this could be used as a biomarker or a diagnostic strategy for PD (Gjerloff et al., 2015) .
Approximately 5-10% of patients present the classical Mendelian inheritance form of PD ("familial PD"), with patients presenting mutations in the genes that have been related to neurodegeneration (e.g., a-synuclein, parkin, tau and ubiquitin cterminal hydrolase) Dexter and Jenner, 2013; Simon-Sanchez et al., 2009) . In spite of that, the most common form of PD is sporadic. It is believed that the interaction of multiple genetic susceptibilities and environmental factors underlie the cause for this idiopathic form of PD (Dawson and Dawson, 2003; Di Monte, 2003) . In addition, biochemical abnormalities such as mitochondrial dysfunction, free radical mediated damage, excitotoxicity, inflammatory change and proteasomal dysfunction have also been reported to mediate PD pathogenesis (Dauer and Przedborski, 2003; Schapira, 2005) . Although it is well known that DAergic neuronal loss is severe in the SNpc at later stages of PD, there is a lack of information regarding the rate and magnitude of this degeneration in the different stages of the disease, particularly in the early stages after diagnosis. Indeed, Kordower and colleagues have recently supported this idea, proposing that such information may be crucial for understanding the natural evolution of PD. By performing a correlation between disease duration and integrity of the nigrostriatal system, these authors found that although PD progresses beyond the first decade, the phenotypic changes in the nigrostriatal pathway are greater than the structural changes. This suggests that the clinical dysfunction that is observed is likely due to a severe loss of function of the nigrostriatal neurons , which may be due to a degeneration of the DAergic terminals and not its loss, thereby indicating that possibly DAergic neurons may be dysfunctional but still potentially viable and recoverable. Nevertheless, answers to these observations require additional studies and tools, particularly in early stages of the disease where there is a greater chance that surviving/viable DAergic neurons benefit from therapy.
Parkinson's disease clinical features
PD clinical features include a variety of motor and non-motor symptoms. Since there are no definitive diagnostic tests for this disease and it may often be confused with other parkinsonian disorders (e.g., essential tremor, multiple system atrophy and progressive supranuclear palsy), clinicians require thorough knowledge of PD clinical manifestations to differentiate it from other conditions. The discovery of new biomarkers specific for PD could obviate this problem in the future.
From the motor point of view, PD is characterized by the appearance of motor cardinal features namely bradykinesia, resting tremor, rigidity, and postural instability (Jankovic, 2008; Koller, 2003; Massano and Bhatia, 2012) . At the onset of the disease, patients typically present asymmetrical tremors, more prominent in the upper extremities (Koller, 2003) . As the disease progresses, patients are equally affected on both sides of the body, with bilateral bradykinesia becoming evident (Koller, 2003) . Later on, patients reveal postural instability, gait dysfunctions (freezing and festination) and severe balance impairments, that frequently lead to falls (Koller, 2003) . Bradykinesia or slowness of movement is the most characteristic clinical feature of PD (Jankovic, 2008) , that manifests by difficulties in initiation, execution and arrest of movement, or in any task requiring fine motor control (Jankovic, 2008; Koller, 2003) . Tremor at rest, particularly in distal part of the extremities, is also one of the most recognizable symptoms of PD (Jankovic, 2008) . Additionally present postural tremor, may also represent a manifestation of PD (Jankovic, 2008; Koller, 2003) . Rigidity is characterized by increased resistance to muscle stretch and relaxation, due to tightness and stiffness of muscles and may occur proximally (e.g., neck, shoulders, hips), distally (e.g., wrists, ankles) or both. It is often associated with pain (e.g., painful shoulder) and, later in the disease, with postural deformities, such as flexed neck and trunk posture, as well as flexed elbows and knees (Jankovic, 2008; Koller, 2003) . In later stages of PD, postural instability also becomes evident as a result of loss of postural reflexes. The latter is usually followed by freezing, a form of movement loss (akinesia) characterized by a sudden transient inability to move, contributing to loss of balance (postural instability) and subsequent falls (Giladi et al., 2001; Jankovic, 2008; Koller, 2003) . Although freezing does not occur universally, it is probably the most disabling of all PD symptoms in more advanced stages. Finally, in certain circumstances, particularly in patients with postural instability and flexed truncal posture, festination of gait (involuntary quickening of gait) may also occur (Koller, 2003) .
Although PD is generally considered a motor control disorder and the cardinal signs of the disease rely on motor disabilities, a variety of non-motor features also emerge due to the degeneration of other neuronal pathways (Koller, 2003) . These non-motor features are commonly known as PD non-motor symptoms and are very frequent, contributing significantly for the morbidity and impaired quality of life of the patients (Hely et al., 2005; Schapira, 2005; Shulman et al., 2001) . They are characterized by neuropsychiatric, autonomic, sensory and sleep abnormalities (Jankovic, 2008; Koller, 2003; Schapira, 2005) . The most frequent neuropsychiatric comorbidities include apathy (anhedonia), dementia, anxiety disorders (e.g., panic attacks), depression, hallucinations, psychosis and impulse control disorders (e.g., obsessive-compulsive and impulse behaviors) (Jankovic, 2008; Koller, 2003; Schapira, 2005) . Autonomic/involuntary nervous system control dysfunctions affect about one third of PD patients (Koller, 2003) . The most common autonomic abnormalities are orthostatic hypotension, sweating dysfunction, bowel problems, constipation, dysphagia (swallowing difficulties), sialorrhoea (excessive production of saliva), sphincter and erectile dysfunction (Jankovic, 2008; Koller, 2003; Schapira, 2005) . Sensory disturbances also affect PD patients, but often pass unrecognized as parkinsonian disturbances (Koller, 2003; Shulman et al., 2002) . These include anosmia (lack of olfaction), akathisia (physical restlessness and subjective urge to move), paresthesias (abnormal sensation of the skin like burning, prickling and formication) and pain (Jankovic, 2008; Koller, 2003) . Finally, sleep disturbances such as excessive sleepiness, sleep attacks, insomnia as well as rapid-eye movement sleep behavior, are also common in PD (Gjerstad et al., 2006 (Gjerstad et al., , 2007 Jankovic, 2008) .
Current clinical therapies in Parkinson's disease

PD pharmacotherapies
The pioneer work of Carlsson and colleagues (1957) on the discovery of DA as a putative neurotransmitter (Björklund et al., 2010) , together with the findings from Ehringer and Hornykiewicz (1960) which revealed that dopamine concentrations were markedly decreased in the striatum of PD patients (Ehringer and Hornykiewicz, 1998) , paved the way for the use of L-DOPA in the clinical setting (Pandey, 2012; Smith et al., 2012) . Indeed L-DOPA revolutionized the treatment of cardinal motor symptoms of PD (rest tremor, rigidity, bradykinesia and postural instability) leading to improved daily function, quality of life and survival of PD patients (Smith et al., 2012) . Over the last decades, L-DOPA has become known as the "gold standard" therapy for PD motor symptoms. However, chronic use of L-DOPA often leads to motor fluctuations and drug-induced dyskinesias (Factor and Weiner, 2008; Schapira, 2005; Smith et al., 2012) . The mechanisms underlying these effects are not completely understood, but are most likely related with the pulsatile stimulation of DA receptors and the degree of striatal denervation (Obeso et al., 2000; Schapira, 2005) . In an attempt to solve these motor complications, dopamine receptor agonists started to be administrated, either alone or as combinatorial therapy with L-DOPA (Lang and Lees, 2002; Schapira, 2005; Smith et al., 2012) . Nevertheless, the use of DA receptor agonists is not free from motor disturbances, often leading to major autonomic and psychiatric side effects that outweigh their beneficial effects in PD patients (Smith et al., 2012) . Currently, two oral (pramipexole, ropinirole), and one injectable (apomorphine), DA receptor agonists are available for administration to these patients (Smith et al., 2012) . They were developed to reduce prevalence of drug-induced dyskinesias in PD patients and their efficacy was later confirmed in large-scale randomized controlled trials (Dewey et al., 2001; Parkinson Study Group, 2000; Rascol et al., 2000) . Besides having specific action in certain DA receptors subtypes, pramipexole and ropinirole have longer halflives, which presumably avoids rapid fluctuations in DA receptors stimulation, thereby managing dyskinesias in such patients (Schapira, 2005; Smith et al., 2012) . However, although pramipexole and ropinirole DA receptor agonists diminish the risk of dyskinesias in PD patients, they often generate major non-motor side effects like psychiatric symptoms (e.g., hypomania, euphoria, paranoia, confusion, delusions, hallucinations), psychiatric disorders (e.g., psychosis, depression, impulse control disorders), autonomic side effects (e.g., orthostatic hypotension) and sleep disorders (Factor, 2008; Kalinderi et al., 2011; Olanow et al., 2009b ; Fig. 2 . Wearing-off typical pattern during the day in PD patients. Smith et al., 2012) . This means that, sooner or later, supplementation with L-DOPA will be required Schapira, 2005) . Therefore, pramipexole and ropinirole are currently being administrated as monotherapy early in the course of PD, or in combination with L-DOPA in mid-to late-stages of the disease. On the other hand, apomorphine is one of the oldest non-ergot shortacting DA receptor agonists, with receptor affinity (D1, D2, D3) similar to the referred neurotransmitter (Factor, 2008; Smith et al., 2012) . Apomorphine is also the only DA receptor agonist that has been shown to possess an anti-parkinsonian efficacy similar to L-DOPA in double-blinded clinical trials (Dewey et al., 2001; Koller, 2003; Smith et al., 2012) . This similarity, together with the shortacting activity of apomorphine, may explain the appearance of autonomic side effects resembling those described for pramipexole and ropinirole, although with a lower prevalence of psychiatric problems (Dewey et al., 2001; Pfeiffer et al., 2007; Smith et al., 2012) . The use of apomorphine for treating PD has been avoided for several years due to its emetic (vomit-inducing) action (Dewey et al., 2001; Koller, 2003) . But the development of an injectable form (apomorphine hydrochloride) allowed to surpass these limitations and nowadays apomorphine is used as an adjuvant to other anti-parkinsonian medications (Dewey et al., 2001; Pfeiffer et al., 2007; Smith et al., 2012) . In spite of its benefits, reported technical difficulties and cutaneous adverse effects, after long-term subcutaneous infusions, made this drug an unattractive choice for PD treatment (Smith et al., 2012) . As consequence, injectable apomorphine is only used in unpredictable motor fluctuations (end-of-dose "wearing off") and "off" episodes in later stage PD patients (Koller, 2003) (Fig. 2) .
Inhibitors of dopamine metabolizing enzymes like monoamine oxidase B (MAO-B), (peripheral) cathecol-O-methyltransferase (COMT) and aromatic L-aminoacid decarboxylase, are other agents presently used for normalizing DAergic transmission. In 1962, monoamine oxidase inhibitors were found to potentiate the antiparkinsonian effect of L-DOPA (Bernheimer et al., 1962; Koller, 2003) .
Currently, selegiline and rasagiline are the most common MAO-B inhibitors used in the treatment of PD (Peretz et al., 2016) . Several clinical guidelines have been established, proposing the initiation of PD treatment with these drugs, in order to delay the introduction of L-DOPA (Connolly and Lang, 2014; Olanow et al., 2001) . Indeed, the efficacy of both drugs has been widely supported (Jost et al., 2014) . Stowe and colleagues (Stowe et al., 2011) suggested in their meta-analysis that selegiline and rasagiline have comparable effects in the treatment of PD. However, this assumption still remains under some controversy. Results from five studies with selegiline and four with rasagiline revealed similar effects in their treatment efficacy (Marconi and Zwingers, 2014) . Nevertheless, in an indirect meta-analysis performed by Jost and colleagues (Jost et al., 2012) , it was reported that rasagiline takes advantage over selegiline, when the UPDRS total score is used. Recently, Peretz and colleagues (Peretz et al., 2016) suggested some possible advantage for selegiline, either because of better symptomatic effects or superiority in its disease-modifying effects, when compared to rasagiline.
Altogether, results revealed that selegiline and rasagiline were effective in early stages of PD, leading to their current adoption as monotherapy in early stages of PD. On the other hand, they can also be used in combination with L-DOPA to reduce motor fluctuations and "off" episodes in advanced PD patients (Factor, 2008; Group, 2005a; Kalinderi et al., 2011; Olanow et al., 2008a Olanow et al., , 2009a Parkinson Study Group, 1989 , 2002 Rascol et al., 2011) . It is also worth mentioning that MAO-B inhibitors were suggested to act as neuroprotective agents (Akao et al., 2002; Bar Am et al., 2004; Jenner, 2004; Maruyama et al., 2002) . However, their potential for displaying neuroprotective properties has been surrounded by controversy (Hart et al., 2009; Olanow et al., 2008a,b; Rascol, 2009) . As reviewed by Knudsen Gerber (2011) both selegiline and rasagiline have been suggested to withhold neuroprotective properties. Still, for selegiline studies have yet to show a definitive conclusion (Fernandez and Chen, 2007) . Meanwhile, the use of rasagiline in clinical studies also demonstrated a delayed and reduced need for future use of L-DOPA (Group, 2005a) .
Inhibitors for COMT (e.g., tolcapone, entacapone) and aromatic L-aminoacid decarboxylase (e.g., carbidopa), have been developed to improve the L-DOPA therapeutic effect (Koller, 2003) . Demonstration of COMT inhibitors (e.g., antacapone, tolcapone) effectiveness in decreasing motor fluctuations in advanced PD patients, when combined with L-DOPA or with L-DOPA-carbidopa (Heikkinen et al., 2002; Larsen et al., 2003; Nutt et al., 1994; Parkinson Study Group, 1997; Poewe et al., 2002; Rinne et al., 1998; Schapira, 2005; Smith et al., 2012) , led to FDA approval for their clinical use.
Anticholinergics are amongst the oldest class of pharmaceuticals used as therapeutic agents for the management of PD (Factor and Weiner, 2008; Koller, 2003; Smith et al., 2012) . Considered the first treatment for PD, the effectiveness of anticholinergic treatments was postulated in the theory stating that the origin of PD motor symptoms was the result of an imbalance between acetylcholine and dopamine in the striatum (Aosaki et al., 2010; Kalinderi et al., 2011) . However, over the years their use has declined, due to the introduction of L-DOPA and dopamine agonists (Aosaki et al., 2010) . Nowadays, it is mainly clinically adopted for the treatment of young patients with PD-associated tremor or dystonia (Koller, 2003; Smith et al., 2012) .
Amantadine is another FDA approved anti-parkinsonian agent. It acts by blocking glutamatergic hyperactivity, which has been associated with PD pathology (Rascol et al., 2011; Smith et al., 2012) . It is the only ionotropic glutamate receptor antagonist that has been shown to have robust antidyskinetic properties in the reduction of L-DOPA-induced dyskinesias (Factor, 2008; Kalinderi et al., 2011; Olanow et al., 2009b; Smith et al., 2012) . Therefore, it is the only drug currently used capable of concomitantly reduce dyskinesia and improve PD symptoms (Ferreira and Rascol, 2000; Koller, 2003) .
A summary of study design and number of patients as well as primary outcome measure, main results and conclusions from trial studies above referenced is provided in Table 1 .
PD surgical interventions
The first reports showing that surgery interventions within the basal ganglia could resolve tremor and rigidity came from the work published by Russel Meyers in 1942 and 1951 (Meyers, 1942 , 1951 . Following this, several groups conducted surgeries based in ablative techniques. At the time, surgical ablation was performed in different basal ganglia locations, such as the anterodorsal and posteriomedial segments of the pallidum (pallidotomy), as well as the ventrolateral and the ventral intermediate segments of the thalamus (thalamotomy) (Alexander et al., 1990; Jankovic et al., 1995; Koller, 2003) . As a consequence of the reported benefits of this type of surgery in improving tremor and rigidity, ablative surgeries (pallidotomy, thalamotomy) became the standard procedure for treatment of PD motor symptoms between the 1950s and the 1960s (Pandey, 2012) . In the 1960s, with the advent of L-DOPA as an effective drug for PD motor symptoms, surgery for PD gradually declined. However, several other events in the past twenty-five years contributed for the reemergence of neurosurgical interventions for PD management. For instance, reversible lesioning by deep brain stimulation (DBS), pioneered by Cooper in the early 1970s (Cooper, 1973; Pereira and Aziz, 2006) , as well as the outcomes provided by non-human primate models of PD in understanding basal ganglia pathophysiology (Aziz et al., 1991; Bergman et al., 1990; Rascol et al., 2011) , provided key insights for the "renaissance" of neurosurgical therapies for PD.
Approved by FDA in 2002, DBS consists in the implantation of internal and external electric stimulators (like a pacemaker device) with the aim of delivering continuous high frequency electric stimulation to areas within the brain (Faggiani and Benazzouz, 2016; Schwalb and Hamani, 2008; Smith et al., 2012) . In fact, when compared to the first surgical procedures in this area, DBS has overtaken pallidotomy in developed countries, since it presents less significant risks (e.g., hemorrhage, infarction, facial palsy, dysphagia, mortality) and adverse effects (e.g., affective disorders; visual fields, speech and cognitive deficits) than the latter (Pereira and Aziz, 2006; Rascol et al., 2011) . DBS of the subthalamic nucleus (STN) and the internal pallidal segment (internal globus pallidus/ GPi) is currently the most commonly applied surgical treatment in patients with tremor, dyskinesias, rigidity and motor fluctuations refractory to the presently available medication (Benabid et al., 2009a,b; Pereira and Aziz, 2006; Rascol et al., 2011; Smith et al., 2012) . Nevertheless, the ideal target for DBS is still a matter of debate. In fact, clinical trials have related STN DBS to significant cognitive and psychiatric side effects, such as depression, apathy, impulsivity, emotional instability and increased risk of suicide (Anderson et al., 2005; Follett et al., 2010; Moro et al., 2010; Okun, 2013; Schupbach et al., 2005; Soulas et al., 2008; Strutt et al., 2012; Taba et al., 2010) . The underlying cause for these events, when reported following DBS surgery either in STN or in the GPi, has not yet been established, but it is thought to involve stimulation of non-motor areas of these targets, along with the limbic structures, as well as pre-surgical psychiatric conditions (Follett et al., 2010; Okun et al., 2009) . A summary of the type of surgery, study design, duration and number of patients as well as the primary outcome measure, main results and conclusions from trial studies referenced in this section is provided in Table 2 .
New drugs and surgical targets for PD
Motor complications associated with long-term L-DOPA treatment, as well as the suggestion that some drugs (e.g., selegiline, Early treatment with rasagiline at a dose of 1 mg/day provided benefits (e.g.: increase in UPPERS scores), consistent with a possible disease-modifying effect. However, early treatment of rasagiline with 2 mg/day did not. Therefore, rasagiline disease modifying effects must be interpreted with caution.
Key: CO (cross-over); DB (double-blind); DS (delayed start); MC (multicenter); MD (multi-dosage); PC (placebo controlled); PG (Parallel group); RD (randomized); UPPERS (Unified PD rating scale); UPPERS I: evaluates mental cognition, behavior and mood disabilities; UPPERS II: evaluates quality of life/activities of daily life disabilities; UPPERS III: evaluates motor impairment; UPPERS VI: evaluates complications of therapy. rasagiline) could have neuroprotective effect on PD, led to the development of new drugs for symptomatic or neuroprotective therapies. Symptomatic drug therapies for motor features of PD, already being tested in clinical trials, involve for instance the use of DAergic drugs such as controlled-release formulations (IPX 066), continuous duodenal infusions of carbidopa-levodopa (LCIG/ Duodopa) and sustained release formulations of L-DOPA (XP 21279). Other strategies have been followed, namely by using drugs targeting non-DAergic neurotransmitter systems, such as adenosine receptor antagonists (e.g., preladenant; tozadenant; caffeine), alpha-2-adrenergic antagonists (e.g., fipamezole), noradrenergic reuptake inhibitors (e.g., methylphenidate), ionotropic (e.g., talampanel) or metabotropic glutamate receptor antagonists (e.g., mavoglurant, dipraglurant), serotonin receptor agonists (e.g., sarizotan, pardoprunox), nicotinic receptor agonists (e.g., nicotine), histamine receptor antagonists (e.g., famotidine), cholinesterase inhibitors (e.g., donepezil, rivastigmine), calcium channel blockers (e.g., isradipine) and endogenous neurotrophic factor inducers (e.g., cogane) [more information on this topic can be found in Hauser (2011), Kalia et al. (2013) and Rodnitzky (2012) ]. Some of the above referred drugs (e.g., nicotine, preladenant) are also being studied in clinical trials for the potential neuroprotective part they can play in the scope of PD (source: clinicaltrials.gov; clinical trial identifiers: NCT01560754, NCT01155479) [more information on this topics in Dunkel et al. (2012) and Kalia et al. (2013) ]. On the other hand, new drugs targeting oxidative-stress (e.g., deferiprone), mitochondrial dysfunction and excitotoxicity (e.g., creatine) (Rascol et al., 2011; Schapira, 2005 ) are also currently being tested in clinical trials (NCT01539837, NCT00449865) to determine their possible neuroprotective role in PD [reviewed by Dunkel et al. (2012) , Kalia et al. (2013) and Rodnitzky (2012) ]. Electrode implantation in patients has also provided insight into the patho-anatomy and pathophysiology of PD. These progresses led to the establishment of possible new targets for DBS such as pedunculo pontine nucleus and caudal zona incerta [reviewed by Sackeim and George (2008) ]. These targets generated interest for DBS in PD patients since some small clinical trials reported anti-parkinsonian effects following the stimulation of either pedunculo pontine nucleus (Ferraye et al., 2010; Plaha and Gill, 2005) or zona incerta (Kitagawa et al., 2005; Plaha et al., 2006) . Therefore, new clinical trials are planned to study pedunculo pontine nucleus (NCT01485276, NCT02318927) and zona incerta (NCT01945567) as potential DBS targets for PD therapy.
Molecular therapies
As discussed before, the long-term use of L-DOPA has been associated with undesirable side effects, such as motor fluctuations and dyskinesias (Schapira, 2005; Smith et al., 2012; Teixeira et al., 2013) . These limitations, together with significant advances made in the study of the pathobiology and patho-anatomy of PD, led to the emergence of new pharmacologic agents and gene engineering approaches for the long-term outcome of PD patients.
Drug therapy
Nowadays, new candidate drugs, still in preclinical studies, focus mainly on neuroprotective agents, as well as on alternative non-DAergic therapies, for PD treatment. Based on recent animal model studies, metabotropic glutamate receptor agonists have raised special attention as potential neuroprotective targets in PD (Marino and Conn, 2006) . Among the type of agonists mentioned, subtype 4 of group III (mGluR4) is mainly localized in presynaptic terminals and mediates inhibitory effects on basal ganglia circuitry, namely on glutamatergic synapses in the striatum and GABAergic synapses in the globus pallidus (Nicoletti et al., 2011; Smith et al., 2012) . DA depletion in PD has been associated with basal ganglia circuitry hyperactivation. Electrophysiological studies have demonstrated that activation of mGluR4 significantly reduces excitatory synaptic transmission within the basal ganglia (Bennouar et al., 2013; Cartmell and Schoepp, 2000) . For these reasons, interest has been raised about the use of mGluR4 agonists, and more recently about enhancers of the mGluR4 agonist effect (positive allosteric modulators), as potential anti-parkinsonian therapies. Indeed, several studies have shown that drugs which activate mGluR4, such as orthosteric agonists (e.g., (2S)-2-amino- 4-[hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitro-phenyl)methyl]phosphoryl]butanoic acid/LSP1-2111) and positive allosteric modulators [(e.g., N-phenyl-7-(hydroxylimino) cyclopropa [b] chromen-1a-carboxamide (PHCCC); (+/À)-cis-2-(3,5-dichlorphenylcarbamoyl)cyclohexanecarboxylic acid/VU0155041, and 5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2amine/ ADX88178)], crossed the brain-blood-barrier and alleviated PD motor symptoms (e.g., akinesia and drug-induced dyskinesias) in animal models (Betts et al., 2012; Beurrier et al., 2009; Niswender et al., 2008) . For instance, allosteric modulators like PHCCC have shown to reduce loss of nigrostriatal dopaminergic neurons in a mice model of PD, following its injection in the external globus pallidus (Battaglia et al., 2006) . Similar results regarding neuroprotection of DAergic neurons and motor benefits were reported by Betts et al. after injection of VU0155041 in the SNpc of a rat model of PD (Betts et al., 2012) . These results suggest that mGluR4 allosteric modulators may play a dual role, by relieving PD motor symptoms and providing neuroprotection of the nigrostriatal pathway. Indeed, recently developed positive allosteric modulators, like ADX88178, demonstrated to improve efficacy in a rodent PD model when combined with L-DOPA and adenosine receptor antagonists (Amalric et al., 2013; Celanire and Campo, 2012) . Taken together, current experimental data on mGluR4 agonist effects on general PD motor symptoms and neuroprotection of the nigrostriatal pathway are promising. Importantly, non-motor side effects should also be assessed in future animal studies. This is a matter to be taken in account, since it was reported in human studies following administration of several ionotropic glutamate receptor antagonists, aimed at blocking increased glutamatergic transmission in the basal ganglia circuitry (Maranis et al., 2012) . In addition to mGluR4 agonists, CEP-1347 has also been proposed as a possible disease modifying agent for the treatment of PD (Parkinson Study, 2004) . CEP-1347 has been described as an anti-apoptotic drug able to inhibit the mixed lineage kinases, which are activators of apoptotic pathways implicated in the pathogenesis of PD (Eggert et al., 2010) . From the application point of view, this drug was found to enhance neuronal survival in a variety of pre-clinical models and also to be safe and well tolerated in PD (Harikrishna Reddy et al., 2014) . Indeed, CEP-1347 did not alter the pharmacokinetics of L-DOPA in PD patients, when both you administered in combination (Parkinson Study, 2004) . Despite these promising observations, application of CEP-1347 remains controversial. In 2007, The Parkinson Study Group PRECEPT Investigators (Parkinson Study Group, 2007) reported that, contrarily to the effects showed in animal models (CEP-1347 acting as a favorable disease-modifying agent), in humans CEP-1347 demonstrated to be an ineffective treatment in early PD. Similar results were also found in a phase II clinical trial conducted with approximately 800 participants, which was terminated because CEP-1347 did not cause any significant decline in PD progression (Group, 2005b) .
GM1 ganglioside has also been described, like CEP-1347, as a potential disease modifying therapy for PD (Pope-Coleman et al., 2000; Schneider et al., 1998) . Being a normal constituent of nerve cell membranes, it is described as a modulator of several cell surface and receptor activities. It also plays a role in neuronal differentiation, protein phosphorylation and synaptic function (Pope-Coleman et al., 2000; Schneider et al., 1995) . GM1 has demonstrated to be effective in ameliorating neurochemical and behavioral alterations both in murine and non-human primate PD models (Herrero et al., 1993; Schneider et al., 1995) . In 1998, Schneider and colleagues (Schneider et al., 1998) , in a randomized double blind placebo trial, showed that the administration of GM1 led to the improvement of UPDRS motor scores and performance in motor tasks from PD patients, when compared to the baseline performance. More recently, in a five-year open study, Schneider and colleagues (Schneider et al., 2010) demonstrated that the longterm application of GM1 in PD patients is safe and may provide some clinical benefits. Nonetheless, these authors also claim the need for future studies to completely address if GM1 may be a symptomatic or disease modifying compound for the treatment of PD (Schneider et al., 2013 (Schneider et al., , 2010 . Following this, in a recent pilot imaging study Schneider and colleagues (Schneider et al., 2015) provided insights about the application of GM1 improving dopamine neurotransmission in patients, which might indicate GM1 as potential disease modifying agent for PD. Although the precise mechanism for this has not been described, studies have claimed that GM1 action in PD patients is multi-factorial (Schneider et al., 2013) . Indeed, in a recent work performed by Hadaczek and colleagues (Hadaczek et al., 2015) it was suggested a potential neuroprotective role of GM1, through GDNF signaling, an important growth factor for the maintenance of DAergic viability.
Coenzyme Q10 (CoQ10), a pivotal enzyme in the oxidative phosphorylation process in mitochondria, has also been presented as a potential disease modifying agent for the treatment of PD (Seet et al., 2014) . However, the clinical evidence for CoQ10 in PD is still conflicting. For instance, Muller and colleagues (Muller et al., 2003) showed significant symptomatic improvements following CoQ10 administration during four weeks, while similarly, Shults and colleagues (Shults et al., 2002) observed long-term benefits of CoQ10 up to 16 months. On the other hand, Storch and colleagues (Storch et al., 2007) , using the same dose that the previous study reported (1200 mg/day), did not observe benefits in mid-stage PD after 3 months of treatment. More recently, in a phase III randomized clinical trial (Parkinson Study Group et al., 2014) , it was demonstrated that CoQ10 was safe and well tolerated in PD patients, but did not present evidence of clinical benefits. Thus, additional trials are still needed to really confirm the potential role of CoQ10 in slowing or modifying the progressive deterioration function in PD.
Finally, N-acetyl-cysteine (NAC) has been described as a thiol antioxidant and a prodrug which can systematically deliver cysteine to the brain (Martinez Banaclocha, 2000; Tarazi et al., 2014) . Studies in animal models have reported that NAC administration leads to the reduction of oxidative damage, by increasing mitochondrial complex I activities and preventing ROS accumulation, leading this way to the protection of dopamineinduced cell death (Clark et al., 2010; Martinez-Banaclocha, 2012) . In a recent clinical trial, Holmay and colleagues (Holmay et al., 2013) demonstrated that, after intravenous injection of NAC, there was a boost in antioxidant glutathione levels on the brain and blood of PD patients. Such increases may compensate the hypothesized deficiency and lower glutathione activity in PD (Jenner, 2003 (Jenner, , 2007 . More recently, Monti and colleagues (Monti et al., 2016) revealed that NAC may support DAergic viability and functionality through dopamine modulation. Nevertheless, more studies are still needed to investigate the potential benefits of NAC in improving PD symptomatology or slowing its progression, whether as a monotherapy, whether or in combination with L-DOPA.
Gene therapy
Gene therapy in PD makes use of viral vectors to carry out gene transfer for targeted protein expression in specific brain areas. In the last decade, the use of gene therapy to relieve PD motor symptoms has reached clinical trials essentially through three approaches: (1) delivery of glutamic acid decarboxylase (GAD) enzyme in the STN; (2) delivery of synthetic enzymes to increase striatal DA levels, and (3) local infusion of neurotrophic factors to protect and restore nigral DAergic neurons (Cummins and Barker, 2012; Rodnitzky, 2012; Smith et al., 2012) .
The rationale behind the first approach is to deliver GAD, the rate-limiting enzyme for GABA synthesis, into the glutamatergic neurons of the STN, using an adeno-associated virus (AAV) vector. This gene therapy approach aims at modulating STN activity, by modifying the phenotype of the STN neurons from predominantly excitatory (glutamatergic) to predominantly inhibitory (GABAergic). With this it is expected that the normal function in striatopallidal circuitry can be restored (Coune et al., 2012; Smith et al., 2012) . Based on preclinical data provided by animal models of PD (Emborg et al., 2007; Lee et al., 2005; Luo et al., 2002) , as well as the reported improvement of motor scores in a phase I open-label study involving 12 moderately advanced PD patients , a phase II, double-blind, randomized, sham-controlled trial enrolling 45 advanced PD patients, was conducted (LeWitt et al., 2011) . Results revealed a modest but significant improvement in UPDRS motor scores of patients bilaterally infused with STN AAV-GAD. The most common adverse effects reported were nausea, headache and depression. A five year follow up of adenoassociated virus serotype 2 (AAV2) vector encoding glutamic acid decarboxylase in the subthalamic nucleus (STN AAV2-GAD) is currently on-going to evaluate long-term effects of AAV-GAD gene transfer and its long-term safety (NCT01301573).
The second gene therapy approach consists of the transfection of dopamine-synthesizing enzymes, to induce DA synthesis in the striatum in order to alleviate PD motor symptoms. So far, two different enzyme replacement therapies have been tested in clinical trials. In the first open label phase I/II trial conducted in 2007, a lentiviral vector containing the genes encoding for the enzymes required for DA biosynthesis (tyrosine hydroxylase/TH, guanosine 5 0 -triphosphate/GTP cyclohydrolase 1 and aromatic amino acid decarboxylase/AADC), under the name of ProSavin, was injected into the striatum to evaluate the safety, efficacy and dosage in 15 mid-to-late stage PD patients, for a period of 6 months (NCT00627588). The Oxford biomedical company recently reported good tolerance of ProSavin. Moreover, motor improvements were observed 6 months after the test had begun, as assessed by UPDRS motor scores. A multicenter, open label study for a ten-year follow-up of patients who were treated with ProSavin to evaluate its long-term safety, tolerability and efficacy for PD treatment is currently ongoing (NCT01856439). The second enzyme replacement therapy, tested in two phase I clinical trials, consisted in bilateral intra-putaminal or intrastriatal delivery of an AAV encoding human AADC gene to induce local conversion of peripheral administered L-DOPA into DA (Christine et al., 2009) . Although preclinical studies in a non-primate model of PD had previously showed that AAV-AADC could induce stable long-term expression of the vector, restore L-DOPA levels, improve motor deficits and reduce L-DOPA side effects in subjects (Bankiewicz et al., 2006 (Bankiewicz et al., , 2000 , both phase I clinical trials reported only modest improvements in UPDRS scores of advanced PD patients. Moreover, in one of the clinical trials (Christine et al., 2009) , some patients suffered from aggravated dyskinesias, most likely due to nonregulated striatal neurons release of DA. A non-randomized open label trial to evaluate safety and efficacy of AAV2-human AADC injected through magnetic resonance imaging guidance is currently being planned (NCT01973543). However, future trials must be designed with caution to avoid excessive production of dopamine in the striatum, since GABAergic striatal neurons do not possess vesicular storage capability. This lack of vesicular structures can result in accumulation of extracellular or cytosolic DA, which in turn may lead to oxidative-stress , dyskinesias (Bankiewicz et al., 2006 (Bankiewicz et al., , 2000 and even to degeneration of striatal neurons Cyr et al., 2003) .
The third gene therapy approach relies on the use of growth factors, such as GDNF, to mediate growth, survival and protection of DAergic neurons within the midbrain (Sherer et al., 2006 ). Due to its tropism for the nigral DAergic neurons, GDNF was amongst the first molecules to be studied (Ai et al., 2003; Grondin et al., 2003 Grondin et al., , 2002 . However, two double-blind trials reported no improvement of Parkinson motor symptoms following infusion of GDNF, either in the lateral ventricles or in the putamen, with many patients suffering from diverse side effects (Lang et al., 2006; Nutt et al., 2003) . Based on these results, the attention has shifted toward neurturin (NTN), a member of the GDNF ligands family that, similarly to GDNF, has shown to promote survival and growth of midbrain DAergic neurons (Kotzbauer et al., 1996) . Recently, the efficacy and safety of an adenovirus vector encoding for human NTN (AAV2-NTN) , under the name CERE-120, has been evaluated in two clinical trials. A phase I clinical trial enrolling 12 PD patients demonstrated good tolerance to AAV2-NTN and an improvement in "off" medication symptoms (Marks et al., 2008) . This led to a phase II multicenter, randomized, double-blind, sham-controlled trial involving intraputaminal injection of AAV2-NTN in 58 patients with moderate to severe PD . However, in this new study results revealed no improvements in UPDRS motor "off" score. Also, contrarily to the results observed in pre-clinical nonhuman primate studies (Herzog et al., 2008 (Herzog et al., , 2007 Kordower et al., 2006) , post-mortem brain analysis of AAV2-NTN treated patients revealed the expression of NTN mainly in the striatum with minimal presence in the SNpc . This result has been associated with the lack of retrograde transportation of NTN to the SNpc and the extensive loss of DAergic neurons in advanced PD patients (Bartus et al., 2011) . Consequently, a new phase I/II trial, in which AAV2-NTN is injected into the SN and the putamen, is presently being conducted in earlier stage patients to evaluate safety and potential beneficial effects of AAV2-NTN over longer periods of time (NCT00985517). So far, phase I has been completed in 6 subjects with no reported complications.
In spite of the encouraging preclinical data, clinical trials based on therapeutic transgenes delivery to basal ganglia neuronal populations failed to confirm the beneficial motor effects observed in animal studies (with the exception of the first approach). This way, genetic approaches still have to prove its long-term efficacy and long-term safety as an alternative therapy for the existing symptomatic treatments. Nevertheless, recent insights on the genetic causes of PD, as well as the development of innovative gene delivery systems, may shed some light on this topic in the years to come.
Cell-based therapies
The hypothesis that therapies using cells could be a good strategy to replace DAergic neurons lost along the course of PD, led to the emergence of cell-based approaches to meet the clinical challenge of restoring degenerated DAergic neural circuitries and provide long-lasting relief of patients symptoms. In this section, the characterization, advantages and disadvantages of each of these cell-based therapies will be further explored.
A summary of the advantages and disadvantages of different stem cell types for application in PD is provided in Table 3 .
Fetal ventral mesencephalic tissue
Fetal ventral mesencephalic (FVM) tissue is derived from the fetuses' midbrain (Shamekh et al., 2008) . The rationale for its transplantation relied on the hypothesis that healthy DAergic neurons are able to reinnervate the striatum and restore physiological DA transmission in the brain. In the late 1970s, several grafting studies were conducted using FVM tissue transplanted either into the lateral ventricle adjacent to the caudate (Perlow et al., 1979) or directly into the striatal parenchyma (Björklund et al., 1980) , on 6-hydroxydopamine (6-OHDA) models of PD. These studies showed that transplantation of DAergic tissue or cells induced the recovery of motor functions, which was associated with graft-derived reinnervation of most of the caudate-putamen. Subsequent studies consistently demonstrated that intrastriatal transplantation of rat fetal SN tissue could reinnervate rat striatum, secrete DA and induce substantial, or even complete, reversion of motor deficits (Björklund and Kordower, 2013; Dunnett et al., 1983 Dunnett et al., , 1988 Koller, 2003) . The extent of the animals' motor recovery largely depended on the extent of nigrostriatal reinnervation and DA restoration following SN transplants. Thus, the observation that animal's behavioral recovery could only be achieved with striatal intra-parenchyma grafting led to the abandonment of intraventricular transplantation (Björklund and Kordower, 2013) . In the late 1980s, the first human open trials were performed and revealed promising results on the long-term survival of DAergic neurons as well as DA synthesis, following human FVM tissue transplantation (Hagell et al., 1999; Koller, 2003; Kordower et al., 1996; Lindvall et al., 1990; Wenning et al., 1997; Widner et al., 1992) . Motivated by these encouraging results, two National Institute of Health funded double-blind placebo-controlled trials were conducted in advanced PD patients (Freed et al., 2001; Olanow et al., 2003) . However, both studies failed to meet their primary outcome concerning long-term survival of DAergic neurons and some patients developed severe graft-induced dyskinetic side effects postoperatively. In addition, Lewy bodies degeneration was observed in the patients that have been examined post-mortem, ten to sixteen years after human FVM tissue transplantation Li et al., 2008; Rascol et al., 2011) . Moreover, methodological and ethics related issues associated with human FVM tissue harvesting have also hindered its use in PD therapeutics (Azari et al., 2010; Teixeira et al., 2013) . Nevertheless, the reported improvement in striatal DAergic neurons and functional outcome in some patients with PD resulted in a currently ongoing phase I European clinical trial (TRANSEURO -NCT01898390). For this trial, an optimized tissue preparation protocol to reduce the graftinduced dyskinesias has been applied.
Embryonic stem cells
Embryonic stem (ES) cells are derived from the inner cell mass of the blastocyst. They are considered to be pluripotent cells due to their capability to differentiate into the three germ layers (endoderm, mesoderm and ectoderm) of the embryo (Salgado et al., 2006) . ES cells are highly proliferative cells, able to maintain their pluripotency for long periods of in vitro expansion (Politis and Lindvall, 2012a) . The possibility of establishing large-scale production of ES cells and to differentiate them into DAergic neurons, led to the possibility of these cells being considered as a tool for generating new cell-based PD therapeutic protocols (Cho et al., 2008; Park et al., 2004; Perrier et al., 2004) . Numerous animal experiments using either rodent or human ES cells-derived dopaminergic neurons showed that these cells could induce functional recovery in animal models of PD (Ben-Hur et al., 2004; Björklund et al., 2002; Brederlau et al., 2006; Kim et al., 2002; Yang et al., 2008b) . Indeed, Björklund et al. and Kim et al., demonstrated that striatal grafted ES cells-derived DAergic neurons were able to survive, integrate and reinnervate the striatum, and this way improve animals' behavior (Björklund et al., 2002; Kim et al., 2002) . Björklund at al. (2002) also observed that the degree of striatal reinnervation was correlated with animals' behavior improvement, an observation that has again been reported by Yang and colleagues (Yang et al., 2008b) . However, despite the consistent description of animals' motor improvement following ES cells-derived DAergic neurons grafting, phenotypic instability of the grafts and consequent tumor formation in rats has also been reported (Brederlau et al., 2006; Roy et al., 2006) . Therefore, issues related with safety and ES cells inappropriate differentiation into midbrain neurons have severely hampered its clinical application. Kriks et al. (2011) has recently readdressed these concerns, which might bring back ES cells into the clinical arena. Still, human ES cells use in clinics is surrounded by controversy related with possible immune rejection of the grafts as well as with safety and ethical issues.
Neural stem cells
Neural stem/precursor cells (NSCs) are multipotent cells, capable of differentiating into the main phenotypes of the central nervous system, namely neurons, astrocytes and oligodendrocytes (Yi et al., 2013) . NSCs can be isolated from developing or adult central nervous system tissue (Bennett et al., 2009; Meyer et al., 2010) and cultured in vitro as free-floating spheres (neurospheres) in the presence of endothelium growth factor and/or basic fibroblast growth factor (Bonnamain et al., 2012) . Their intrinsic properties, and the prospect of using them for replacement of lost DAergic neurons and reconstitution of the DAergic transmission, raised great interest in the use of NSCs as a source for cell replacement therapy in PD.
The first studies using undifferentiated embryonic or fetal NSCs, isolated from cortical and midbrain areas of rodent developing brain, not only reported poor survival and differentiation of striatal grafted cells into DAergic neurons in animal models of PD, but also only mild amelioration of lesion induction deficits (Svendsen et al., 1997; Svendsen et al., 1996) . In addition, these and other studies have consistently reported that only NSCs isolated from the midbrain could differentiate into DAergic neurons (Meyer et al., 2010; Sanchez-Pernaute et al., 2001; Storch et al., 2001 Storch et al., , 2004 . Since then most transplantation studies use either rodent Sawamoto et al., 2001; Schwarz et al., 2006) or human fetal NSCs (Sanchez-Pernaute et al., 2001 ) differentiated into DAergic neurons in vitro prior to transplantation. These studies showed that striatal transplantation of fetal NSCs-derived DAergic neurons resulted in histological, biochemical and functional recovery in animal models of PD. Moreover, one of these studies reported NSCs to have a milder immune rejection and lower risk of tumor formation than ES cells (Schwarz et al., 2006) . However, despite these encouraging results, a low percentage of the transplanted cells survived and/or adopted the DAergic phenotype in vivo after both short-and long-term in vitro expansion of NSCs Sawamoto et al., 2001; Schwarz et al., 2006) . These results, together with the mild-benefits observed in the functional recovery of PD animals reported in earlier studies (Svendsen et al., 1997 (Svendsen et al., , 1996 , have been associated with NSCs dependence on developmental signals (e.g., fibroblast growth factor 8 and Sonic hedgehog) and transcription factors (e.g., nuclear receptor realated-1 protein) implicated in DAergic neurons development (Perrone-Capano and Di Porzio, 2000; Storch et al., 2004) . Parish et al. proposed that an alternative method to address this issue was through the culture of genetically engineered NSCs cells, together with developmental signals necessary for inducing DAergic neurons differentiation in vivo (Parish et al., 2008) . Using this alternative method, the generation of higher yields of functional DAergic neurons in vitro, along with an enhancement in TH-positive cells engraftment and in striatal reinnervation in vivo, was obtained. These improvements were followed by complete behavior recovery of parkinsonian rodents, without tumor formation (Parish et al., 2008) . Nevertheless, longterm follow up of the animals should be provided in order to ensure safety of these engineered cells. Despite the progresses achieved with mesencephalic derived NSCs, the long-term survival and phenotype stability of grafted DAergic neurons in animal models of PD still remains to be demonstrated. Therefore, standardization of protocols ensuring the control of NSCs differentiation into homogeneous populations of DAergic neurons should be established and their transplantation effects in parkinsonian models must be further explored.
Induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) recently emerged in the field of regenerative medicine, following the pioneer studies provided by Takahashi and colleagues (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) in which the authors showed that fibroblasts derived from mice or humans could be re-programmed into pluripotent stem cells. These studies demonstrated that iPS cells presented morphological and phenotypical properties similar to ES cells, particularly pluripotency and generation of viable chimeras (Brundin et al., 2010; Takahashi et al., 2007; Takahashi and Yamanaka, 2006) . Subsequent studies showed that iPS cells not only exhibited genomic stability and transcription profiles similar to ES cells, but were also able to use the same transcriptional network and developmental patterning cues as them to differentiate into DAergic neurons (Brundin et al., 2010; Gibson et al., 2012; Swistowski et al., 2010; Wernig et al., 2008) . In reality, these cells can hold advantages over ES cells, such as the possibility of generating patient specific donor cells for autologous transplantation and this way avoid both immune rejection and ethical concerns related with the use of ES cells (Wernig et al., 2008) .
Studies on transplantation of iPS cells into the striatum of PD animals, either obtained from mice or PD patients somatic cells, provided proof-of-principle for their ability to survive and induce functional benefits in PD animals (Hargus et al., 2010; Swistowski et al., 2010; Wernig et al., 2008) . However, these studies also reported variability in the differentiation pattern of iPS cells into DAergic neurons in vivo. It has also been observed that tumor (teratoma) formation can occur if iPS cells grafts are not fully differentiated prior to transplantation (Wernig et al., 2008) . Moreover, DAergic neurons differentiated from patient-derived iPSCs exhibit a remarkable reduction in the number of neurites and an increased accumulation of autophagic vacuoles when compared to DAergic neurons derived from iPSCs of healthy controls (Sanchez-Danes et al., 2012).
Induced neural cells
In an attempt to address the complications related with incomplete and unsynchronized differentiation of iPS cells observed in vivo (Hargus et al., 2010; Wernig et al., 2008) , an interesting alternative approach, consisting in directly reprograming one somatic cell type into another, was proposed some years ago by Melton and colleagues (Zhou et al., 2008) . Vierbuchen et al. have also reprogrammed fibroblasts into functional neurons in vitro using a similar combinatorial strategy of three neural-specific transcription factors (Brundin et al., 2010; Vierbuchen et al., 2010) . The resulting cells were named induced neural cells (iN cells). These cells have shown the capability to generate DAergic neurons in vitro, while avoiding the reversion to a pluripotent stage, therefore diminishing the risk for tumor formation. However, the ability of these iN cells-derived DAergic neurons to induce benefits on PD animals' phenotype remains to be demonstrated (Caiazzo et al., 2011; Gibson et al., 2012; Pfisterer et al., 2011) .
Mesenchymal stem cells
Mesenchymal stem/stromal cells (MSCs) were initially reported by Friedenstein and colleagues, that defined cells isolated from bone marrow as plastic-adherent fibroblast colony-forming units with clonogenic capacity (Friedenstein et al., 1974) . These cells were named in 1991 as marrow "stromal cells" by Eaves et al., based on their possible use as a feeder layer for hematopoietic stem cells (Eaves et al., 1991) . In that same year, these cells also became known as mesenchymal stem cells on the basis of the report on their clonogenicity and ability to undergo multilineage differentiation, published by Caplan and colleagues (Caplan, 1991) . Currently MSCs are defined, according with the International Society for Cellular Therapy criteria, as multipotent cells, capable of selfrenewal and of differentiating into adipocytes, osteoblasts and chondroblasts (Emsley et al., 2005) . Additionally, MSCs have also been characterized by their ability to adhere to tissue culture plastic and to display the presence of cells surface markers (CD105, CD73, CD90), as well as the lack of hematopoietic cell surface markers (CD45, CD34, CD14 or CD11b, CD79a or CD19 and Human Leukocyte Antigen DR) (Dominici et al., 2006) . So far, MSCs have been isolated from bone marrow (BMSCs), adipose tissue (ASCs), dental pulp, placenta, amniotic fluid, umbilical cord blood, umbilical cord Wharton's jelly (WJ-MSCs/HUCPVCs), liver, lung and spleen (Teixeira et al., 2013) . They have been reported to be isolated with minimal invasive procedures; easily cultured and expanded in vitro for several passages; used for autologous transplantation in virtue of their hypo-immunogenicity (probably related with their surface expression of major histocompatibility complex antigens); have less probability of being tumorigenic and, as adult cells, not hindered by ethical concerns (Kishk and Abokrysha, 2011; Salgado et al., 2006; Seo and Cho, 2012; Teixeira et al., 2013) . These features have made MSCs attractive tools for tackling central nervous system neurodegenerative diseases. Indeed, a considerable body of evidence has revealed the potential of such cells to promote protection and/or recovery of DAergic neurons, against neurotoxin-induced nigrostriatal degeneration, following intrastriatal Bouchez et al., 2008; Cova et al., 2010; Khoo et al., 2011; McCoy et al., 2008; Sadan et al., 2009; Weiss et al., 2006) intranigral (Mathieu et al., 2012; Somoza et al., 2010) , intrathecal (Salama et al., 2012) intravenous (Chao et al., 2009; Wang et al., 2010) and intranasal (Danielyan et al., 2011) delivery of BMSCs, ASCs or WJ-MSCs in rodent or non-human primate models of PD. The mechanisms underlying in vivo functional recovery following MSCs transplantation are, however, a matter of intense debate.
Several groups have focused on the application of MSCs as replacers of injured DAergic neurons, using neuronal-induced MSCs -prior to transplantation -in PD animal models (Baer and Geiger, 2012; Hermann et al., 2004; Jiang et al., 2002; Mitchell et al., 2003; Munoz-Elias et al., 2004; Phinney and Prockop, 2007) . Indeed, several authors have reported that BMSCs-, ASCs-and WJMSCs-derived DAergic neurons transplantation into the striatum, of both rodent and primate models of PD, survived for long periods and increased the levels of DAergic markers. Motor improvement was also described (Hayashi et al., 2013; Levy et al., 2008; Offen et al., 2007; Shetty et al., 2009; Wang et al., 2013; Zhou et al., 2013a) . In addition, two of these studies have reported detectable levels of DA in culture medium following in vitro BMSCs differentiation into DAergic phenotype or DA release after depolarization by potassium stimulation (Hayashi et al., 2013; Shetty et al., 2009) . Similar outcomes were also described after intranigral transplantation of undifferentiated WJ-MSCs and WJderived DAergic neurons in a 6-OHDA rodent model of PD (Shetty et al., 2013) . In this study, the authors further compared the effect of either naïve or differentiated BMSCs and WJ-MSCs in parkinsonian animals. Results revealed that, both naïve and differentiated WJ-MSCs were able to significantly improve the motor behavior, although this effect was more striking in differentiated WJ-MSCs transplanted animals. In contrast, Bouchez et al. reported similar beneficial effects on animals' behavioral recovery after intrastriatal transplantation of either BMSCs cultured in standard conditions or in neuronal differentiation medium (Bouchez et al., 2008) . On the other hand, McCoy et al. showed that ASCs were able to protect DAergic neurons and ameliorate animals' functional deficits against neurotoxin-induced neurodegeneration, without the need of DAergic differentiation (McCoy et al., 2008) . Comparable to what Bouchez et al. and McCoy et al. found, other researchers have reported no in vivo differentiation of in vitro neural-induced MSCs (Chao et al., 2009; Khoo et al., 2011) , after intrastriatal or intravenous transplantation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-OHDA rodent models of PD. Also, robust data failed to provide robust evidence regarding MSCs differentiation into full functional neurons (Liu et al., 2012; Thomas et al., 2011; Trzaska et al., 2007) . Therefore, it seems unlikely that MSCs differentiation into neuronal lineages is the major contributor for MSCs-induced recovery in PD.
In recent years, MSCs regenerative effects have been related to their secretome, that is, to the panel of bioactive soluble factors and vesicles with neuroregulatory properties released by these cells to the extracellular environment (Teixeira et al., 2013) . Different tissue derived MSCs not only seem to sense local environment, but have also shown to respond to signals that are up-regulated under injury conditions by migrating to the damage site. Once there, they promote cell regeneration and limit the extent of tissue damage through the secretion of soluble growth factors (GFs), antiinflammatory cytokines and microvesicles/exosomes (Caplan and Dennis, 2006; Ding et al., 2007; Li et al., 2002; Meirelles Lda et al., 2009; Neuhuber et al., 2005; Yang et al., 2008a) . The effect of these soluble factors can be generally classified into neuroprotective/anti-apoptotic, neurogenic, angiogenic and synaptogenic. Such effects are commonly mediated by the secretion of the following factors by MSCs (Chen et al., 2000 (Chen et al., , 2001a Ding et al., 2007; Hu et al., 2010; Li et al., 2002; Lin et al., 2011; Lopatina et al., 2011; Neuhuber et al., 2005; Wakabayashi et al., 2010; Wei et al., 2009; Wright et al., 2007 ): brain-derived neurotrophic factor (BDNF), GDNF, nerve growth factor, hepatocyte growth factor, vascular endothelial growth factor, vascular endothelial growth factor receptor 3, angiopoietin 1, insulin-like growth factor 1, insulin-like growth factor 2, endothelium growth factor, basic fibroblast growth factor, fibroblast growth factor 20, granulocyte colony-stimulating factor, platelet-derived growth factor AA, chemokine ligand 16, neutrophil-activating-protein-2 and neurotrophin-3 growth factors, as well as interleukin-6, interleukin-10, transforming growth factor beta 1, stem cell factor, stromal cellderived factor 1 and monocyte chemotactic protein 1 cytokines.
In the context of PD, several studies have also demonstrated that BMSCs secretome has a protective and/or regenerative character on DAergic neurons in in vitro and in vivo models of PD Cova et al., 2010; Danielyan et al., 2011; Kim et al., 2009; McCoy et al., 2008; Park et al., 2012; Sadan et al., 2009; Shintani et al., 2007; Wang et al., 2010; Weiss et al., 2006) . For instance, Shintani and coworkers demonstrated that BMSCs conditioned media was able to promote survival of TH-positive DAergic neurons in rat primary cultures of ventral mesencephalic cells (Shintani et al., 2007) . Moreover, intrastriatal transplantation of fetal mesenchephalic cells, pre-treated with human BMSCs conditioned media, induced survival of DAergic grafted cells and promoted functional recovery in a 6-OHDA rat model of PD (Shintani et al., 2007) . The observed protection of DAergic neurons was attributed to BMSCs secretion of BDNF, GDNF and basic fibroblast growth factor, all of which had previously shown to stimulate survival of DAergic neurons (Shintani et al., 2007; Teixeira et al., 2013) . Similarly, Sadan et al. showed not only that human BMSCs cultured in the presence of growth factors significantly increased the viability of the SH-SY5Y neuroblastoma cell line exposed to 6-OHDA, but also that BMSCs transplanted into the striatum of a 6-OHDA rat model of PD migrated to the lesion site, increased the number of TH-positive cells and the DA levels (Sadan et al., 2009) . These neuroprotective and neuro-regenerative effects were accompanied by a reversion of behavioral impairments and were correlated with BMSCs secretion of significant amounts of BDNF and GDNF. Likewise, this expression pattern is in accordance with data published by Blandini and colleagues using the same animal model . On the other hand, Wang and colleagues associated rat-derived BMSCs expression of stromal cell-derived factor 1a with DAergic neurons protection against 6-OHDA neurotoxin, both in vitro and in vivo, through antiapoptotic based mechanisms (Wang et al., 2010) . Moreover, Cova et al. demonstrated that human BMSCs transplanted into the striatum of a 6-OHDA rodent model of PD were able to survive and interact with the lesion site surroundings, thus enhancing survival of DAergic terminals and neurogenesis in the SVZ in a sustained manner . Importantly, BMSCs in vitro secretion of neurogenic (endothelium growth factor, neurotrophin-3, BDNF), neurodevelopmental, neurorescuing and lesion home-mediating GFs (vascular endothelial growth factor, hepatocyte growth factor, basic fibroblast growth factor), along with the active secretion of BDNF in vivo, were correlated with the activation of endogenous stem cells and striatal/nigral DAergic protection against neurodegeneration induced by 6-OHDA . Similarly, Park et al., using a MPTP mice model of PD, reported that BMSCs were able to modulate neurogenesis through the production of endothelium growth factor (Park et al., 2012) .
In addition to the capability of BMSCs to induce survival and restorative effects on DAergic neurons, they also present immunomodulatory and anti-inflammatory properties. In this context, Danielyan and coworkers recently showed that intranasally delivered rat BMSCs to 6-OHDA exposed rats migrated toward the SN and the striatum, and prevented the decrease of DA in lesioned brain areas (Danielyan et al., 2011) . Moreover, a substantial improvement of animals' motor function was also observed. These neuroprotective effects and functional recovery of the DAergic system have been associated with the increase of BDNF levels in the lesioned hemisphere side as well as with the BMSCs capacity to modulate the host immune response and exert a strong anti-inflammatory activity. Indeed, MSCs are known to modulate the response of inflammatory cells by decreasing the expression of pro-inflammatory cytokines, such as interleukin 1b, interleukin 2, interleukin 12, tumor necrosis factor a and interferon g (Danielyan et al., 2011; Meirelles Lda et al., 2009) . The secretion of interleukin-6, interleukin-10 and transforming growth factor b anti-inflammatory cytokines by BMSCs was also related with the protection of nigral DAergic neurons, by other authors (Kim et al., 2009) .
Some other studies have also demonstrated that ASCs and WJMSCs secretome induces DAergic neurons survival in 6-OHDA models of PD, as well as an improvement in animals' motor impairments (McCoy et al., 2008; Weiss et al., 2006) . For instance, Weiss et al. showed that WJ-MSCs transplantation in a 6-OHDA model of PD could increase the number of TH-positive cells and ameliorate PD animal behavior through the secretion of GDNF and fibroblast growth factor 20 (Weiss et al., 2006) . Using the same animal model, McCoy et al. also demonstrated that intranigral transplantation of ASCs increased both the survival and protection of DAergic neurons in the lesioned area and ameliorated animals' motor deficits through the secretion of nerve growth factor, BDNF and GDNF (McCoy et al., 2008) . The same authors also observed that ASCs attenuated microglial activation in the lesioned SNpc and suggested that this capacity to modulate microglial activity could be related with ASCs secretion of anti-inflamatory molecular mediators (McCoy et al., 2008) .
From the above referred studies, it is clear that there is increasing evidence indicating that the neuroprotective and neuroregenerative effects of MSCs observed in PD are attributed to the secretion of soluble GFs and cytokines. MSCs secretion of these factors not only protects DAergic neurons from further degeneration and enhances endogenous reparative processes (e.g., neurogenesis), but also acts as inflammation and immune response modulator. Moreover, recent reports have shown that besides soluble GFs and cytokines, MSCs also secrete microvesicles and exosomes containing miRNA, which are believed to mediate cell-to-cell communication and act as reparative agents (Baglio et al., 2012; Zhou et al., 2013b; Zhu et al., 2013 (Xin et al., 2012 ).
Future perspectives
As reviewed by Onofrj and colleagues (Onofrj et al., 2008) , satisfactory approaches that slow down PD, by protecting DAergic neurons from premature death, are missing.
As it was already described, the current symptomatic treatment relies in the reestablishment of dopamine levels through the use of L-DOPA, DA agonists (e.g., ropinirole or pramipexole), MAO-B (e.g., rasagiline or selegiline) and COMT (e.g., entacapone or tolcapone) inhibitors, to compensate its deficits in the nigrostriatal dopaminergic pathway. Although efficacious, these molecules cannot induce the recovery of lost DAergic neurons or to protect those that have not yet been impacted by the disease (Onofrj et al., 2008) . Moreover, it is nowadays accepted that several other factors contribute to PD progression besides DA deficits in the nigrostriatal pathway namely, mitochondrial dysfunction, reactive oxygen species, ubiquitination, proteasomal dysfunction and neuroinflammation (Yadav et al., 2014) . This way, some questions should be raised: will there be alternative strategies to L-DOPA? Can we combine the use of L-DOPA with other therapeutic strategies to improve its action, and reduce side effects and dosages? Such questions represent at the present time one of the major challenges of PD research.
Safinamide ((S)-(+)-2-[4-(3-fluorbenzyloxybenzylamino)propanamide]methanesulfonate), a MAO-B inhibitor and a blocker of N-methyl-D-aspartate glutamate receptor (NMDAR) and sodium/calcium channels, has been presented as a promising therapeutic option for PD (Perez-Lloret and Rascol, 2016) . Recently licensed by European Medicines Agency (EMA) as an "add-on" therapy, it has been described as an enhancer of dopaminergic transmission, presenting decreased secondary effects when compared to L-DOPA (Fabbri et al., 2015; Stocchi and Torti, 2016) . In addition, neuroprotective effects have also been attributed to safinamide, preventing/inhibiting the formation of toxins or free radicals by oxidative stress and glutamate/gammaaminobutyric acid (GABA) release, thereby reducing the excitotoxic input in DAergic neuronal death (Perez-Lloret and Rascol, 2016) . From the application point of view, safinamide has already demonstrated to have a high oral bioavailability, presenting satisfactory levels of safety, tolerability and efficacy both in preclinical and clinical assays (Caccia et al., 2006; Fabbri et al., 2015) . For instance, when compared to other MAO-B inhibitors like selegiline or rasagiline, it revealed to be a potent modulator of DA, exhibiting a highly selective and reversible MAO-B inhibition, with a level of selectivity for MAO-B clearly superior to the above referred drugs (Caccia et al., 2006) . Such evidence represents a crucial advantage, particularly for patients who experience adverse effects and need to be treated with other drugs, in which case the reversibility of safinamide avoids potential drug interactions. Also, when safinamide was added to a single DA agonist, a superior benefit was achieved (Stocchi et al., 2004) . Even when combined with the standard treatment L-DOPA, safinamide was able to significantly increase its availability in the serum. This result suggests that such effect is accomplished by safinamide itself, due to the putative inhibition of DA reuptake through MAO-B inhibition and not due to the inhibition of metabolizing enzymes, such as dopadecarboxylase or catechol-O-methyltransferase (COMT) (Onofrj et al., 2008) . Despite these promising results, to the best of our knowledge, there are no studies reporting the effects of safinamide in drug naïve patients and even in early stages of PD (Cattaneo et al., 2016; Fabbri et al., 2015; Muller, 2016) . Such experiments could in the future open unprecedented opportunities to change PD research and its therapeutic approaches.
Along the same line as safinamide, there is opicapone, a novel, once-daily and potent third-generation cathecol-O-methyltransferase inhibitor (Ferreira et al., 2015a; Scott, 2016) . Recently approved, oral opicapone is, like safinamide, an adjunct therapy to L-DOPA, to be used in adults with PD and end-of-dose motor fluctuations who cannot be stabilized (Devos and Moreau, 2015; Scott, 2016) . Described as a hydrophilic 1,2,4-oxadiazole analog with pyridine N-oxide residue at position 3, this drug provides a high COMT inhibitory action, without inducing relevant cytotoxicity in cells (Kiss et al., 2010) . Indeed, in pre-clinical models, opicapone was found to prolong the inhibitory effect on peripheral COMT and extend the bioavailability of L-DOPA, without inducing toxicity (Bonifacio et al., 2015) . Similarly, on Cynomolgous monkeys, the referred drug was also found to not only increase the systemic exposure to L-DOPA, but also to increase its levels in the dorsal striatum and substantia nigra (Bonifacio et al., 2014) . Even from the clinical point of view, Ferreira and colleagues (Ferreira et al., 2015b) demonstrated that opicapone significantly reduced COMT activity, increasing the systemic exposure to L-DOPA, which translated in an improved motor response by the patients, when compared to placebo. When it was applied in healthy volunteers, a pronounced effect was also observed in increasing L-DOPA bioavailability when compared to other COMT inhibitor, such as entacapone (Rocha et al., 2014) . More recently, Ferreira and colleagues (Ferreira et al., 2015a) showed that a single take (daily) of opicapone could enable a simplified drug regimen, allowing for a decrease on the total daily L-DOPA dose and leading to an increase of dose intervals, thereby reducing the number of intakes and maximizing its benefits. Such evidence opens interesting new perspectives for PD treatment since, altogether, data suggests opicapone to be a promising alternative to the current available COMT inhibitors, simplifying PD drug regimens and increasing patient's quality of life (Fabbri et al., 2016) .
In addition to these two promising drugs, there are also some new perspectives concerning DBS (Wichmann and DeLong, 2016) . Indeed, it has been claimed that understanding how DBS could affect multiple cortical regions downstream, would be an important advance in its use as a therapeutic approach (Alhourani et al., 2015) . Understanding also the network effects of DBS will allow tailoring the treatment based on biomarkers related to those effects. It is this way expected to achieve an increase on therapeutic efficacy and avoid undesirable side effects (Humphries and Gurney, 2012; Paek et al., 2015) . Nevertheless, although promising, it still has some limitations, namely the inability to (totally) recover/ protect DAergic neurons after PD onset. Therefore, the field's current view is that combinatory strategies may overcome the limitations of single drug/surgical approaches, particularly by combining them with stem cell-based strategies.
hMSCs secretome has recently been proposed as an alternative therapeutic tool for PD, given its ability to modulate DAergic neuronal survival (Teixeira et al., 2016a) . In fact, using secretome as a therapeutic approach, rather than transplanting cells, would be a valuable tool in overcoming technical concerns associated to the latter (e.g., number of cells needed and cell delivery). Recently it has been demonstrated that hMSCs secretome can be successfully modulated using dynamic culture conditions through computercontrolled bioreactors (Teixeira et al., 2016b) . Also, some studies have shown that molecules secreted by hMSCs promote nervous tissue regeneration through activation/modulation of endogenous neuro-restorative processes. In the future, such molecules could be an efficacious add-on if combined with cell transplantation, pharmacological or surgical strategies (Buttery and Barker, 2014; Choi et al., 2010; Rowland et al., 2015; Yao et al., 2016) . Although most of the available results support hMSCs secretome as a promising cell-free therapy and a potential off-the-shelf product for PD, current sources of MSCs do not allow for the isolation of a sufficient number of cells for their widespread clinical use, instead relying on invasive, expensive and labor-intense isolation protocols that yield MSCs with limited proliferative capacity (Teixeira et al., 2016b) . Therefore, inducible pluripotent stem cells (iPSCs) have been suggested as a possible alternative source for obtaining large populations of MSC-like cells (iMSCs) (Jung et al., 2012; Kang et al., 2015) . In fact, the use of iPSCs as a new possible therapeutic tool and also as a source of MSCs could be a breakthrough, since it yields a more homogenous population of MSCs, and probably is more robust in enhancing secretome production and potential. As recently assumed by Lian and colleagues (Lian et al., 2010) , the greater potential of iPSCs and iMSCs may be related with their ability to survive and proliferate longer whether in culture or after transplantation, thereby being a more robust promising approach than the classical adult MSCs. Thus, the establishment of patientspecific iPSCs/iMSCs and their secretome could present an unprecedented opportunity to change PD research, by redefining the disease in its molecular and cellular basis.
iPSCs have also been proposed as a promising in vitro model that covers all the complexity of PD, allowing this way for research in many, if not all, of the features of this pathogenesis, either from sporadic or familial cases (Soldner et al., 2009 ). This approach may also allow to predict (new) therapeutic outcomes for experimental PD treatments, alone or in combination (e.g., PD drugs, DBS or iMSCs/iPSCs secretome), as well as to track PD progression through the identification of new therapeutical targets. This way maybe one day we might understand how to prevent or slow down degeneration of DAergic neurons.
Conclusions
PD is the second most prevalent neurodegenerative disorder, characterized by a variety of motor and non-motor features. With the significant advances made in the fields of etiology, pathobiology and patho-anatomy of PD, new pharmacologic agents, gene engineering and cell replacement therapeutic approaches have been developed to meet the clinical challenge of treating or modifying the course of the disease. Although important progresses have been achieved, there are still important gaps missing, particularly on better methods to induce regenerative processes in the areas affected by the disease. In order to overcome this, in the future it will be important to understand the true potential of emerging technologies, such as those derived from iPSC or MSCs secretome, as well as how these may be combined with existing molecular and pharmacotherapies. Doing so, it will be possible to tackle PD in a multi-dimensional and more effective way.
